Compare AMH & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMH | ABVX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.9B |
| IPO Year | 2012 | 2022 |
| Metric | AMH | ABVX |
|---|---|---|
| Price | $30.68 | $87.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 12 |
| Target Price | $37.11 | ★ $164.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.4M |
| Earning Date | 11-04-2026 | 09-21-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 9.26 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $1,182,836,000.00 | N/A |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $3.48 | $1,702.77 |
| P/E Ratio | $46.76 | ★ N/A |
| Revenue Growth | ★ 3.45 | N/A |
| 52 Week Low | $27.22 | $69.81 |
| 52 Week High | $35.07 | $148.83 |
| Indicator | AMH | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 31.72 |
| Support Level | $30.30 | $74.79 |
| Resistance Level | $31.18 | $128.68 |
| Average True Range (ATR) | 0.47 | 3.70 |
| MACD | 0.11 | -0.26 |
| Stochastic Oscillator | 54.94 | 22.09 |
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.